September 30, 2019
Pharmaceutical companies Bausch Health, Assertio, Salix, Santarus and Lupin now face at least five class actions alleging that they participated in a yearslong scheme that catapulted prices for diabetes drug Glumetza up to more than $3,000 for one month's supply.